These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir. Honda T; Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M Bioorg Med Chem Lett; 2002 Aug; 12(15):1925-8. PubMed ID: 12113810 [TBL] [Abstract][Full Text] [Related]
32. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313 [TBL] [Abstract][Full Text] [Related]
33. Zanamivir: from drug design to the clinic. Elliott M Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388 [TBL] [Abstract][Full Text] [Related]
34. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor. von Itzstein M; Wu WY; Jin B Carbohydr Res; 1994 Jun; 259(2):301-5. PubMed ID: 8050102 [No Abstract] [Full Text] [Related]
35. The low potential for drug interactions with zanamivir. Daniel MJ; Barnett JM; Pearson BA Clin Pharmacokinet; 1999; 36 Suppl 1():41-50. PubMed ID: 10429839 [TBL] [Abstract][Full Text] [Related]
37. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. Thompson CI; Barclay WS; Zambon MC J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666 [TBL] [Abstract][Full Text] [Related]
40. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically]. Kaji M Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]